Relative bioavailability study of fixed dose combination tablet formulation of GSK587323 (16mg candesartan cilexetil/12.5mg hydrochlorothiazide) under fasting conditions

Not Applicable

Completed

• Registration Number: CTRI/2014/04/004526
• Lead Sponsor: GlaxoSmithKline Research and Development Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 16

Inclusion Criteria

Male and females aged between 18 and 65 years of age inclusive, at the time of signing the informed consent

Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria,outside the reference range for the population being studied may be included only if

the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.

Body weight >= 50kg and BMI within the range 19 â?? 24.9kg/m2 (inclusive)

Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit

Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

ALT, alkaline phosphatase and bilirubin <= 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

Based on single or averaged QTc of triplicate ECGs obtained over a brief recording period: QTcF < 450 msec

Exclusion Criteria

Gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug

Any subject with a systolic BP <95mmHg or with a recent history of postural symptoms

Study & Design

• Study Type: BA/BE
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the relative bioavailability of a candidate formulation of candesartan and HCTZ following administration of a FDC of 16mg candesartan cilexetil/12.5mg HCTZ (GSK587323) relative to reference FDC of 16mg candesartan cilexetil/12.5mg HCTZ (Atacand D) in healthy human subjects under fasting conditions. <br/ ><br>Plasma PK parameters including Cmax, AUC(0-â??) and AUC(0-t) for candesartan cilexetil and HCTZ in <br/ ><br>relevant treatmentsTimepoint: Twenty-four (24) blood samples (1 x 6 mL)pre-dose (0.00) and at 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

Secondary Outcome Measures

Name	Time	Method
To characterise secondary PK parameters of a candidate FDC tablet formulation of 16mg candesartan cilexetil/12.5mg HCTZ (GSK587323) relative to reference 16mg candesartan cilexetil/12.5mg HCTZ (Atacand D) in healthy human subjects under fasting conditions. <br/ ><br> <br/ ><br>Plasma PK parameters: tmax, %AUCex and t½Timepoint: Twenty-four (24) blood samples (1 x 6 mL)pre-dose (0.00) and at 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose